drugset / Trial / NCT00185965
CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Phase 1/2
Completed
30 enrolled
Ronald Levy
American Society of Clinical Oncology · collabLymphoma Research Foundation · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Brief summary TBD
Timeline
- Start
- 2004-07
- Primary completion
- 2010-03
- Completion
- 2010-03
Publications
- Results Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, Morales A, Abdulla F, Xing L, Navi D, Tibshirani RJ, Advani RH, Lingala B, Shah S, Hoppe RT, Levy R. In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood. 2012 Jan 12;119(2):355-63. doi: 10.1182/blood-2011-05-355222. Epub 2011 Nov 1.
- Results Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010 Oct 1;28(28):4324-32. doi: 10.1200/JCO.2010.28.9793. Epub 2010 Aug 9.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | agatolimod | Oligonucleotide (other) | 6 mg | Other |